The Ro, Hims, LifeMD, WeightWatchers Partnership Map

Ro, Hims, LifeMD, WeightWatchers, and Sesame are the authorized telehealth partners for brand-name GLP-1 distribution. Here's the partnership map and what it means for access.

The U.S. GLP-1 telehealth market in 2026 is increasingly defined by a small set of authorized commercial partnerships between brand-name manufacturers (Novo Nordisk and Eli Lilly) and consumer-facing telehealth platforms (Ro, Hims & Hers, LifeMD, WeightWatchers, Sesame Care, and others). This partnership map walks through who is partnered with whom, on what terms, and what the consumer-facing implication is for each platform.

The NovoCare Authorized Telehealth Partners

As of April 2026, the primary authorized telehealth partners for Wegovy distribution through NovoCare are Hims & Hers, Ro, WeightWatchers Clinic, LifeMD, and Sesame Care. The March 31, 2026 subscription launch at $249/month was a joint announcement across these five partners. Each operates an authorized clinical workflow: licensed clinician evaluation, NovoCare-authorized pharmacy fulfillment, and compliance with NovoCare program standards on marketing, pricing, and patient experience.

How the Partnerships Actually Work

Under an authorized telehealth partnership, the manufacturer provides preferred pricing in exchange for adherence to specific program standards. The telehealth platform handles patient acquisition, clinical evaluation, ongoing support, and consumer relationship. The pharmacy fulfillment is routed through the manufacturer's authorized specialty pharmacy network. The patient experience is typically: sign up with the telehealth platform, complete a clinical intake, meet with a licensed clinician (usually video or asynchronous), receive a prescription, have the medication shipped from an authorized pharmacy, and receive ongoing clinical monitoring.

The $249/month subscription price is the preferred partnership price available through authorized channels. It is a discount to the NovoCare direct $349 price, reflecting the volume and patient-acquisition value the telehealth platforms bring to the manufacturer relationship.

Lilly Partnerships for Zepbound

Lilly's authorized telehealth partnerships for Zepbound operate through LillyDirect as the manufacturer-facing program, with telehealth platforms participating in clinical evaluation, ongoing support, and fulfillment coordination. Ro, LifeMD, and WeightWatchers are major participants. Sesame Care facilitates Zepbound access through its direct-care clinician network. The vial pricing ($299-$449) available through LillyDirect is typically what patients pay regardless of which telehealth intake path they use, though platforms may bundle additional clinical services.

The Sesame Care Distinction

Sesame Care operates on a slightly different model than the subscription-driven telehealth brands. Sesame is a direct-care marketplace where patients book and pay for individual consultations with licensed clinicians, receive a prescription if clinically appropriate, and can fill that prescription through standard pharmacy channels or manufacturer direct programs. Sesame emphasizes brand-name FDA-approved medications and has been consistent in that positioning across its GLP-1 offering. For patients who prefer a pay-per-visit model over subscription commitment, Sesame is the primary authorized option.

What the Partnership Structure Means for Patients

For patients, the partnership map means that the ecosystem of trustworthy, compliant GLP-1 access points has consolidated around a manageable number of authorized providers. The subscription price at $249/month is roughly equivalent across the subscription partners, which removes price as a differentiator and pushes competition to clinical experience, customer service, education, and ancillary services. Patients can choose based on which platform fits their preferred clinical workflow rather than hunting for the lowest price.

What's Notable by Absence

A few platforms that were prominent in the compounded GLP-1 era are less visible in the authorized brand-name partnership map. Some have transitioned fully to brand-name distribution and are now authorized partners; others have exited the GLP-1 category or pivoted to adjacent services. The consolidation reflects the broader market transition from compounded-era abundance of providers to authorized-era preferred partnerships.

For related reporting, see our Novo-Hims partnership deep dive and Wegovy pricing timeline.

Affiliate Disclosure: Some provider links on this page are affiliate links. If you sign up through these links, we may receive compensation at no additional cost to you. This does not influence our editorial content, pricing data, or provider selection.